MarketLens
Sign Up

Has Xeris Biopharma Reached an Inflection Point

3 months ago
SHARE THIS ON:

Has Xeris Biopharma Reached an Inflection Point

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News2 weeks ago

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Dianthus Therapeutics holds ~$1.2B in cash, supporting late-stage programs through 2030. Claseprubart's differentiated profile strengthens its bull case after Sanofi's setback, reducing funding risk a...
Stock News2 weeks ago

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Xeris Biopharma reported record 2024 revenues of $203M, up 24%, and guided 2025 revenue to $255M–$275M, implying ~30% growth at midpoint. XP-8121, a once-weekly levothyroxine, targets a $1B+ U.S. mark...
Stock News2 months ago

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris issued a corrected release with additional details on inducement grants under Nasdaq Rule 5635(C)(4).

Breaking News

View All →

Top Headlines

View More →
Stock News45 minutes ago

Prediction: Sept. 10 Will Be a Big Day for Nvidia Shareholders.

Stock News2 hours ago

QQQ vs QQQM: Same Index, Same Stocks, Different Fee – and the Math Says One Leaves You Thousands Richer

Stock News2 hours ago

Qualcomm CFO on Amazon AI Deal, Data Center Strategy

Stock News3 hours ago

Meta Targets Mass Market Automation With New Muse AI Agent

Stock News3 hours ago

Nvidia vs. Broadcom: Comparing Recent Quarterly Revenue Trajectories